Pleckstrin homology-like domain family A, member 3 (PHLDA3) is a p53-regulated tumor suppressor protein that suppresses AKT-mediated survival and oncogenic signaling. ThePHLDA3gene has garnered significant attention due to its multifaceted roles in tumorigenesis, metastasis, and invasion. This review explores the complex interactions between PHLDA3 and key cellular processes involved in cancer, emphasizing its regulatory mechanisms and clinical relevance. PHLDA3 has been found to be a critical regulator of metastatic pathways, particularly through its influence on the epithelial–mesenchymal transition (EMT) and in cellular invasion. Its interactions with pivotal signaling pathways, such as the Phosphoinositide 3-kinases/Protein kinase B (PI3K/AKT), p53, and Wnt/β-catenin pathways, highlight its multifunctional roles in various cancer types. Additionally, we discuss the potential of PHLDA3 as both a prognostic biomarker and a therapeutic target, offering new insights into its potential in treating advanced-stage malignancies. This review provides a detailed analysis of the role of PHLDA3 in cancer progression, including metastasis and invasion, underscoring its therapeutic potential.
Pleckstrin同源样结构域家族A成员3（PHLDA3）是一种受p53调控的肿瘤抑制蛋白，能够抑制AKT介导的细胞存活与致癌信号传导。PHLDA3基因因其在肿瘤发生、转移和侵袭过程中的多重作用而受到广泛关注。本综述探讨了PHLDA3与癌症关键细胞过程之间的复杂相互作用，重点阐述其调控机制及临床相关性。研究发现，PHLDA3是转移通路的关键调节因子，尤其通过影响上皮-间质转化（EMT）和细胞侵袭发挥作用。其与磷酸肌醇3-激酶/蛋白激酶B（PI3K/AKT）、p53及Wnt/β-连环蛋白等关键信号通路的相互作用，凸显了其在多种癌症类型中的多功能角色。此外，本文讨论了PHLDA3作为预后生物标志物和治疗靶点的潜力，为晚期恶性肿瘤的治疗提供了新视角。本综述详细分析了PHLDA3在癌症进展（包括转移和侵袭）中的作用，并强调了其治疗潜力。
The Role of PHLDA3 in Cancer Progression and Its Potential as a Therapeutic Target
肿瘤(癌症)患者之家